Literature DB >> 6195131

LB-Q1 and LB-Q2: two determinants defined in the primed lymphocyte test and independent of HLA-D/DR, MB/LB-E, or SB.

A Termijtelen, S J van den Berge, J J van Rood.   

Abstract

The primed lymphocyte test (PLT) was used to prepare reagents between HLA-D/DR identical individuals. Two sets of primed lymphocytes were obtained which recognized the new determinants referred to as LB-Q1 and LB-Q2, respectively. LB-Q2 is significantly associated with HLA-A1, -B8, and -D/DR3. Nevertheless, LB-Q1 and LB-Q2 seem to be distinct from any of the established HLA antigens. No association with any of the alleles of the SB system was observed. A recombination between HLA-D/DR and HLA-B suggested that the locus encoding LB-Q2 is situated on the telomeric side of HLA-D/DR.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6195131     DOI: 10.1016/0198-8859(83)90076-9

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  3 in total

1.  Polymorphisms within the HLA-DR3 haplotypes. I. HLA-DR polymorphisms detected at the protein and DNA levels are reflected by T-cell recognition.

Authors:  R Bontrop; M Tilanus; M Mikulski; M van Eggermond; A Termijtelen; M Giphart
Journal:  Immunogenetics       Date:  1986       Impact factor: 2.846

2.  Mapping SB in relation to HLA and GLO1 using cells from first-cousin marriage offspring.

Authors:  A Termijtelen; P Meera Khan; S Shaw; J J van Rood
Journal:  Immunogenetics       Date:  1983       Impact factor: 2.846

3.  A minor subset of HLA-DR3 haplotypes is preferentially increased in type 1 (insulin-dependent) diabetes.

Authors:  M J Sheehy; J R Rowe; T C Fuller; E J Yunis; K H Gabbay
Journal:  Diabetologia       Date:  1985-12       Impact factor: 10.122

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.